Answers are grounded in this paper and cite their sources.
Colorectal cancer (CRC) remains a leading cause of cancer incidence and mortality worldwide, and metastatic disease responds poorly to conventional surgery, chemotherapy, and targeted therapy. Antibody-drug conjugates (ADCs) link monoclonal antibodies to cytotoxic payloads through chemical linkers, enabling antigen-specific delivery, intracellular payload release, bystander killing, and Fc-mediated immune effects. ADC efficacy and safety depend on target antigen selection, antibody design, payload choice, linker stability, and internalization efficiency. This narrative review, based on literature and trial data available up to February 2026, summarizes the CRC treatment landscape, ADC mechanisms and component optimization, and clinical progress of ADCs targeting HER2, HER3, TROP-2, CEACAM5, and c-MET. No ADC has been approved specifically for CRC; trastuzumab deruxtecan has tumor-agnostic accelerated approval for HER2 IHC 3+ solid tumors and may cover eligible patients with metastatic CRC. Early trials show promising activity but substantial hematologic, gastrointestinal, hepatic, and interstitial lung disease toxicity, reflecting a narrow therapeutic window. We discuss challenges including target specificity, off-target toxicity, drug resistance, and linker stability, and outline future directions such as probody-drug conjugates, bispecific and dual-payload ADCs, novel payloads, and bioorthogonal linkers to support precision therapy for CRC.
No takes yet. Share an insight, caveat, or question.
Cai et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: